Colistin Monotherapy versus Colistin plus Sitafloxacin for Therapy of Carbapenem-Resistant Acinetobacter baumannii Infections: A Preliminary Study
Open Access
- 26 November 2022
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 11 (12) , 1707
Abstract
The in vitro study of sitafloxacin against carbapenem-resistant (CR) Acinetobacter baumannii demonstrated activity against most strains of CR A. baumannii, and the combination of colistin and sitafloxacin showed an in vitro synergistic effect against CR A. baumannii. This study aimed to compare efficacy and safety between colistin plus sitafloxacin with colistin alone for therapy for CR A. baumannii infection. This randomized controlled trial enrolled 56 patients with CR A. baumannii infection (28/group) during 2018–2021, and the treatment duration was 7–14 days. The study outcomes were 28-day mortality, clinical and microbiological responses, and adverse events. There was no significant difference in 28-day mortality between groups (32.1% combination vs. 32.1% monotherapy, p = 1.000). Favorable clinical response at the end of treatment was comparable between groups (81.5% combination vs. 77.8% monotherapy, p = 0.788). Microbiological response at the end of treatment was also comparable between groups (73.1% combination vs. 74.1% monotherapy, p = 0.934). Acute kidney injury was found in 53.8% of the combination group, and in 45.8% of the monotherapy group (p = 0.571). In conclusion, there was no significant difference in 28-day mortality between the colistin monotherapy and the colistin plus sitafloxacin groups. There was also no significant difference in adverse events between groups.Keywords
Funding Information
- Health Systems Research Institute (Nonthaburi, Thailand)
- Faculty of Medicine Siriraj Hospital, Mahidol University (Bangkok, Thailand)
This publication has 25 references indexed in Scilit:
- Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complexJournal of Microbiology, Immunology and Infection, 2015
- In vitro activity of sitafloxacin against carbapenem-resistant Acinetobacter baumanniiInternational Journal of Antimicrobial Agents, 2013
- Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical TrialClinical Infectious Diseases, 2013
- Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infectionsJournal of Infection and Chemotherapy, 2013
- ‘Old’ antibiotics for emerging multidrug-resistant bacteriaCurrent Opinion in Infectious Diseases, 2012
- SitafloxacinDrugs, 2011
- Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, ThailandInternational Journal of Infectious Diseases, 2007
- Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjectsXenobiotica, 2001
- Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve methodJournal of Antimicrobial Chemotherapy, 1996
- Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolatesAntimicrobial Agents and Chemotherapy, 1992